AMICUS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.57 USD | +0.74% |
|
+3.68% | -32.56% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,482 | 6,017 | 3,218 | 3,430 | 4,161 | 2,835 | - | - |
| Enterprise Value (EV) 1 | 2,179 | 5,923 | 3,125 | 3,529 | 4,263 | 3,016 | 2,919 | 2,583 |
| P/E ratio | -6.58 x | -21.6 x | -12.6 x | -14.9 x | -27.8 x | -45.4 x | 43.5 x | 12.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 13.6 x | 23.1 x | 10.5 x | 10.4 x | 10.4 x | 5.56 x | 4.41 x | 3.34 x |
| EV / Revenue | 12 x | 22.7 x | 10.2 x | 10.7 x | 10.7 x | 5.91 x | 4.54 x | 3.04 x |
| EV / EBITDA | -7.28 x | -24.9 x | -15.6 x | -17.1 x | -61.5 x | -689 x | 23.7 x | 8.83 x |
| EV / FCF | -8.06 x | -25 x | -15.1 x | -20.7 x | -55.7 x | 569 x | 14.1 x | 9.29 x |
| FCF Yield | -12.4% | -3.99% | -6.6% | -4.83% | -1.8% | 0.18% | 7.09% | 10.8% |
| Price to Book | 5.22 x | 21.1 x | 10.5 x | 27.9 x | 26.1 x | 12.8 x | 6.84 x | 3.83 x |
| Nbr of stocks (in thousands) | 254,810 | 260,588 | 278,646 | 280,945 | 293,257 | 296,199 | - | - |
| Reference price 2 | 9.740 | 23.09 | 11.55 | 12.21 | 14.19 | 9.570 | 9.570 | 9.570 |
| Announcement Date | 3/2/20 | 3/1/21 | 2/24/22 | 3/1/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 182.2 | 260.9 | 305.5 | 329.2 | 399.4 | 510.2 | 642.8 | 849.3 |
| EBITDA 1 | -299.3 | -238.2 | -200.2 | -206.8 | -69.34 | -4.379 | 123.4 | 292.5 |
| EBIT 1 | -304 | -247 | -206.4 | -212.1 | -77.21 | -9.057 | 110.1 | 275.6 |
| Operating Margin | -166.84% | -94.68% | -67.57% | -64.43% | -19.33% | -1.78% | 17.13% | 32.46% |
| Earnings before Tax (EBT) 1 | -355.9 | -274.3 | -241.6 | -242 | -150.1 | -59.13 | 73.07 | 245 |
| Net income 1 | -356.4 | -276.9 | -250.5 | -236.6 | -151.6 | -64.14 | 68.33 | 219.2 |
| Net margin | -195.56% | -106.12% | -81.98% | -71.85% | -37.96% | -12.57% | 10.63% | 25.81% |
| EPS 2 | -1.480 | -1.070 | -0.9200 | -0.8200 | -0.5100 | -0.2108 | 0.2199 | 0.7602 |
| Free Cash Flow 1 | -270.4 | -236.5 | -206.4 | -170.3 | -76.53 | 5.3 | 206.9 | 278 |
| FCF margin | -148.39% | -90.66% | -67.55% | -51.74% | -19.16% | 1.04% | 32.19% | 32.73% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 167.66% | 95.03% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 302.8% | 126.78% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 3/1/21 | 2/24/22 | 3/1/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 82.15 | 78.72 | 80.73 | 81.69 | 88.1 | 86.27 | 94.5 | 103.5 | 115.1 | 110.4 | 121.4 | 133.1 | 145.3 | 142.5 | 156.5 |
| EBITDA 1 | -70.63 | -67.31 | -59.28 | -32.55 | -41.02 | -36.38 | -16.65 | -14.8 | -1.51 | -25.57 | -8.953 | 1.547 | 6.934 | - | - |
| EBIT 1 | -72.15 | -75.34 | -60.61 | -33.84 | -42.33 | -37.64 | -18.86 | -17.02 | -3.692 | -27.72 | -3.118 | 5.803 | 14.7 | 9.272 | 20.62 |
| Operating Margin | -87.82% | -95.71% | -75.08% | -41.42% | -48.05% | -43.63% | -19.96% | -16.45% | -3.21% | -25.11% | -2.57% | 4.36% | 10.12% | 6.51% | 13.17% |
| Earnings before Tax (EBT) 1 | -80.3 | -81.45 | -61.25 | -29.26 | -70.08 | -53.22 | -40.52 | -24.7 | -31.66 | -43.58 | -14.29 | -4.275 | 5.803 | -2.746 | 9.253 |
| Net income 1 | -83.28 | -85.26 | -62.16 | -33.29 | -55.86 | -52.93 | -43.23 | -21.58 | -33.84 | -48.42 | -16.58 | -6.589 | 3.944 | -2.746 | 9.253 |
| Net margin | -101.37% | -108.31% | -76.99% | -40.75% | -63.41% | -61.36% | -45.75% | -20.85% | -29.41% | -43.86% | -13.66% | -4.95% | 2.71% | -1.93% | 5.91% |
| EPS 2 | -0.2900 | -0.3000 | -0.2100 | -0.1200 | -0.1900 | -0.1800 | -0.1500 | -0.0700 | -0.1100 | -0.1600 | -0.0542 | -0.0204 | 0.0137 | -0.008510 | 0.0307 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 5/9/22 | 8/4/22 | 11/7/22 | 3/1/23 | 5/10/23 | 8/8/23 | 11/8/23 | 2/28/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 98.4 | 102 | 182 | 84.2 | - |
| Net Cash position 1 | 303 | 94 | 93.1 | - | - | - | - | 251 |
| Leverage (Debt/EBITDA) | - | - | - | -0.4758 x | -1.466 x | -41.52 x | 0.682 x | - |
| Free Cash Flow 1 | -270 | -237 | -206 | -170 | -76.5 | 5.3 | 207 | 278 |
| ROE (net income / shareholders' equity) | -87% | -72.6% | -84.4% | -110% | -107% | -36.8% | 16% | 34.5% |
| ROA (Net income/ Total Assets) | -43.5% | -31.9% | -28% | -29% | -5.13% | 14.3% | 30.5% | - |
| Assets 1 | 820.1 | 868.4 | 895.8 | 814.7 | 2,957 | -449.1 | 224 | - |
| Book Value Per Share 2 | 1.870 | 1.090 | 1.100 | 0.4400 | 0.5400 | 0.7500 | 1.400 | 2.500 |
| Cash Flow per Share 2 | -1.040 | -0.9000 | -0.7500 | -0.5800 | -0.2300 | 0.0800 | 0.4300 | - |
| Capex 1 | 20 | 3.23 | 3.88 | 3.77 | 7.44 | 5.16 | 5.15 | 7.29 |
| Capex / Sales | 10.98% | 1.24% | 1.27% | 1.14% | 1.86% | 1.01% | 0.8% | 0.86% |
| Announcement Date | 3/2/20 | 3/1/21 | 2/24/22 | 3/1/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.57
USD
Average target price
17.3
USD
Spread / Average Target
+80.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.56% | 2.83B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- FOLD Stock
- Financials Amicus Therapeutics, Inc.